The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of Keytruda (pembrolizumab), an anti-PD-1 therapy, in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumors express PD-L1 (Combined Positive Score ≥10) and who have not received prior chemotherapy for metastatic disease.
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
